Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
New York University School of Medicine Genentech |
---|---|
Information provided by: | New York University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00134134 |
The purpose of this study is to determine the effectiveness and safety of efalizumab in treating hydradenitis suppurativa, and to evaluate the duration of the benefit seen in people who respond to treatment with efalizumab, after the medication is stopped.
Condition | Intervention | Phase |
---|---|---|
Hidradenitis Suppurativa |
Drug: efalizumab |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label Assessment of the Efficacy & Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa |
Estimated Enrollment: | 5 |
Study Start Date: | February 2005 |
Estimated Study Completion Date: | August 2006 |
The primary objective of this study is to assess the efficacy of subcutaneously administered efalizumab in the treatment of refractory, severe hydradenitis suppurativa. The secondary objectives of this study are to assess the ability to re-establish disease control after discontinuation of drug and allowance for relapse of disease, as well as to assess the safety of subcutaneously administered efalizumab in the treatment of refractory, severe hydradenitis suppurativa.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, New York | |
New York University School of Medicine, Dept of Dermatology | |
New York, New York, United States, 10016 |
Principal Investigator: | Bruce Strober, MD, PhD | New York University School of Medicine |
Study ID Numbers: | H12452-01B |
Study First Received: | August 23, 2005 |
Last Updated: | September 7, 2006 |
ClinicalTrials.gov Identifier: | NCT00134134 |
Health Authority: | United States: Food and Drug Administration |
hidradenitis suppurativa efalizumab biologic Raptiva |
Bacterial Infections Skin Diseases, Infectious Skin Diseases Skin Diseases, Bacterial |
Suppuration Hidradenitis Hidradenitis suppurativa Hidradenitis Suppurativa |
Sweat Gland Diseases Infection |